Navigation Links
Patrick Hwu, M.D., and Mario Sznol, M.D., Join Genesis Biopharma's Scientific and Medical Advisory Board
Date:5/25/2011

LOS ANGELES, May 25, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer therapies, today announced that Patrick Hwu, M.D., and Mario Sznol, M.D., have joined the Company's recently formed Scientific and Medical Advisory Board (SMAB).

Dr. Hwu is currently on the faculty of the University of Texas MD Anderson Cancer Center in Houston, and serves as chairman of the Center's Department of Melanoma Medical Oncology, Division of Cancer Medicine.

Dr. Sznol is currently on the faculty of Yale University School of Medicine, and is Professor of Medicine (Medical Oncology), and also serves as Vice-Chief Medical Oncology and Co-Director of the Yale Cancer Center Melanoma Program.

"We are pleased that Drs. Hwu and Sznol have joined our new Scientific and Medical Advisory Board, and look forward to their contribution in helping to guide our autologous cell therapy program," said Anthony J. Cataldo, President and Chief Executive Officer.

Drs. Hwu and Sznol join other leading oncologists and cancer researchers on the prestigious Genesis Biopharma SMAB who include: Cassian Yee, M.D., Professor of Medicine at the University of Washington's Fred Hutchinson Cancer Research Center; James Mule, Ph.D., and Jeffrey Weber, M.D., Ph.D., of the H. Lee Moffitt Cancer Center & Research Institute; David DiGiusto, Ph.D., of the City of Hope; and Daniel Powell, Ph.D., from the University of Pennsylvania School of Medicine.

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged in the development of targeted cancer therapies.  For more information about the company, visit www.genesis-biopharma.com.

Forward-Looking Statements

The foregoing press announcement contains forward-looking statements that can be identified by such terminology as "ex
'/>"/>

SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. GeneNews appoints Patrick Terry as lead strategic advisor for U.S. commercialization of ColonSentry(TM)
2. Patrick Soon-Shiong, M.D. and Michele B. Chan Join Prestigious List of Recipients of KCET Visionary Award at 10th Gala Honoring Region's Philanthropic Leaders
3. Patrick Soon-Shiong, M.D. and Michele B. Chan Join Prestigious List of Recipients of KCET Visionary Award at 10th Gala Honoring Region's Philanthropic Leaders
4. Healthcare Distribution Management Association Names Patrick Kelly New Senior Vice President, Government Affairs
5. Patrick Dempsey Teams up With Breakaway from Cancer® to Help Connect Cancer Patients to Free Resources
6. Trusted LASIK Surgeons Welcomes Leading LASIK Eye Surgery Expert, Inventor David Huang, M.D., Los Angeles, to Its Unique Lasik Directory Service
7. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
8. Cato T. Laurencin, M.D., Ph.D. to Join Osteotech Board of Directors
9. Senesco Appoints Harlan W. Waksal, M.D., to Board of Directors
10. Ethan Weiss, M.D., Joins Bionovos Scientific Advisory Board
11. Cerimon Pharmaceuticals Appoints James S. Shannon, M.D., to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... , May 20, 2013 Cempra, ... on developing differentiated antibiotics to meet critical medical ... announced that it presented data at the American ... Philadelphia demonstrating the antibacterial and ... Cempra,s prior Phase 2 clinical trial in outpatients ...
(Date:5/20/2013)... 20, 2013 Recognizing exciting and ... members to its 2013 Class of Young Professors. ... will provide this outstanding international group with more ... basic science to meet global challenges.     , The ... promising young and untenured research faculty working in ...
(Date:5/19/2013)... Switzerland’s MS Tûranor PlanetSolar , the ... record for a transatlantic crossing by a solar electric ... 25, 2013, the solar powered boat sailed 2,867miles (5,310 ... of 5.3 knots before reaching Marigot, St. Martin, in ... first-of-its-kind catamaran completed this year’s passage across the Atlantic ...
(Date:5/17/2013)... rejection occurs when the transplant recipient,s immune system identifies ... It was previously thought that T cells, the immune ... molecules known as chemokines in order to migrate to ... Journal of Clinical Investigation , Fadi Lakkis and colleagues ... that chemokine stimulation of T cells is not required ...
Breaking Biology Technology:Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP) 2DuPont Celebrates Scientific Innovation by Recognizing Young Professors 2DuPont Celebrates Scientific Innovation by Recognizing Young Professors 3MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 2MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 3MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 4MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 5MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 6
... LEUVEN, Belgium, August 27 ThromboGenics NV,(Euronext Brussels: THR), a ... for eye disease, vascular disease,and cancer, is today issuing a ... period ending 30 June, 2009. , ... which,are key to its aim of becoming a profitable, integrated ...
... Massachusetts and CHEADLE, England, August 27 ,Cardea Technology, ... and configure their software tools for Vertebral Fracture,Assessment, ... on bone,densitometers, to exchange information and create reports ... Optasia Medical Ltd. has developed SpineAnalyzer(TM), a ...
... , , ATLANTA, Aug. 27 ... million extension of its Series C financing which was originally completed in ... $5 million in Series C preferred stock received warrants for an additional ... have up to 30 days from the delivery of Phase III top-line ...
Cached Biology Technology:ThromboGenics NV Announces Business Update and Half Year Results 2009 2ThromboGenics NV Announces Business Update and Half Year Results 2009 3ThromboGenics NV Announces Business Update and Half Year Results 2009 4ThromboGenics NV Announces Business Update and Half Year Results 2009 5ThromboGenics NV Announces Business Update and Half Year Results 2009 6ThromboGenics NV Announces Business Update and Half Year Results 2009 7ThromboGenics NV Announces Business Update and Half Year Results 2009 8ThromboGenics NV Announces Business Update and Half Year Results 2009 9ThromboGenics NV Announces Business Update and Half Year Results 2009 10ThromboGenics NV Announces Business Update and Half Year Results 2009 11ThromboGenics NV Announces Business Update and Half Year Results 2009 12ThromboGenics NV Announces Business Update and Half Year Results 2009 13ThromboGenics NV Announces Business Update and Half Year Results 2009 14ThromboGenics NV Announces Business Update and Half Year Results 2009 15Cardea Technology Inc and Optasia Medical Ltd Announce Plans to Collaborate to Optimize Their Vertebral Fracture Assessment Tools 2Alimera Sciences Closes $5 Million in Extended Series C Financing 2
(Date:5/18/2013)... presented at Digestive Disease Week (DDW) explores new ... lifestyle. , Individuals suffering from Crohn,s disease ... and poor quality of life. These symptoms can ... randomized, double blind, placebo-controlled study found for the ... significant relief of these symptoms. , "Our ...
(Date:5/17/2013)... Atlanta residents of all ages will celebrate the ... impact on our daily lives during the inaugural ... engineers and educators from local museums, corporations, K-12 ... than 40 different events for children and adults ... http://atlantasciencefestival.org . , The annual Atlanta ...
(Date:5/17/2013)... The Federation of American Societies for Experimental Biology ... Institutes of Health (NIH) funding trends highlighting the devastating ... critical research. The FASEB analysis follows a May 15th ... MD, PhD, who testified that the $1.6 billion cut ... is "having a substantial impact on the scientific community." ...
Breaking Biology News(10 mins):Research examines new methods for managing digestive health 2Research examines new methods for managing digestive health 3First Atlanta Science Festival set for 2014 2
... A University of Leicester archaeologist has discovered a ... Staffordshire - believed to be the earliest archaeological evidence ... As reported in Post-Medieval Archaeology (volume 44/1) ... significance of the find is in the insights it ...
... your wedge may not help much, but mixing in longer ... studies have shown that variable practice improves the brain,s memory ... task. Cognitive neuroscientists at USC and UCLA describe the neural ... Nature Neuroscience . The researchers split 59 volunteers ...
... for regulating viruses that has worked its way into ... adult and fetal hemoglobin production, Medical College of Georgia ... to more targeted therapies for sickle cell patients whose ... throughout the body. Fetal hemoglobin, on the other ...
Cached Biology News:Archaeology find sheds new light on family pets 2Why (smart) practice makes perfect 2Modulator of fetal hemoglobin switch may target sickle cell disease 2Modulator of fetal hemoglobin switch may target sickle cell disease 3
MOUSE ANTI HUMAN CYTOKERATIN 1-8...
GOAT ANTI HUMAN PSA (ISOFORM 1)...
... Immunogen: Synthetic peptide derived from the N-terminal ... ZO-1. Specificity: Specific for the N-terminus ... Reactivity: Human Dog Rat Mouse (positive controls: ... mouse liver heart blood vessel and brain ...
p-Raf-1 (Ser 338/Tyr 341)-R...
Biology Products: